Related Experiment Videos
Compliance in a screening program for neuroblastoma
P Campion1, W G Woods, B Lemieux
1Department of Pediatrics, University of Sherbrooke Medical Center, Quebec, Canada.
Insights
Routine infant screening for neuroblastoma in Quebec achieved high compliance rates. This public health initiative demonstrated that an informed population readily participates in cancer screening programs.
Area of Science:
- Pediatric Oncology
- Public Health Initiatives
- Cancer Screening
Background:
- The Quebec Screening Program for neuroblastoma aimed to reduce mortality from this childhood cancer.
- The study involved over 476,000 infants born in Quebec between 1989 and 1994.
- Screening was offered at 3 weeks and 6 months of age to maximize voluntary participation.
Purpose of the Study:
- To evaluate the effectiveness of a routine infant screening program for neuroblastoma.
- To determine if screening could decrease the mortality rate associated with neuroblastoma.
- To assess population compliance with a voluntary cancer screening program.
Main Methods:
- Urine samples were collected on filter paper, analyzing catecholamine metabolites (vanillylmandelic acid and homovanillic acid).
- Parents mailed samples to a central laboratory for analysis.
- Public awareness campaigns targeted parents, health professionals, and the general public to boost compliance.
Main Results:
- High compliance rates were achieved: 91% at 3 weeks and 74% at 6 months.
- The population demonstrated a positive response to the public health screening measure.
- The screening program successfully engaged a large cohort of infants.
Conclusions:
- Informed populations accustomed to voluntary infant screening for metabolic diseases are receptive to cancer screening.
- Public health strategies effectively increase awareness and participation in screening programs.
- Routine screening can be a viable public health approach for childhood cancers like neuroblastoma.
Background:
The Quebec Screening Program for neuroblastoma was undertaken to determine if routine screening of infants for neuroblastoma would decrease the mortality rate from this cancer. All 476,603 children born in Quebec during a 5-year period (1989 to 1994) were offered this screening at ages 3 weeks and 6 months. Through various strategies, an attempt was made to attain the highest level of voluntary compliance possible.
Methods:
Each screening consisted of the analysis of the catecholamine metabolites vanillylmandelic acid and homovanillic acid on a dry, urine-saturated filter paper mailed to a central laboratory by the parents. The strategies employed to optimize compliance consisted of increasing the awareness of the parents, health professionals, and the public about neuroblastoma and the screening program.
Results:
The population responded well to this public health measure, with a 91% compliance rate at 3 weeks and a 74% compliance rate at 6 months.
Conclusions:
A well-informed population accustomed to voluntary screening for metabolic disease in infants responds well to screening for cancer.